STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #6 by analyst upside · 2026-06-27
RVPH
Reviva Pharmaceuticals Holdings, Inc.
Healthcare · Market Cap $8M · P/E 0x
ANALYST PRICE TARGET
+4066.7%
implied upside to consensus target
Current Price $0.6
Consensus Target $25.0
Bull Target $40.0
Bear Target $5.0
Analysts Covering 3
ANALYST CONSENSUS — HOLD
Strong Buy
0
Buy
2
Hold
0
Sell
1
52-Week Low $0.26
52-Week High $17.2
YTD Return -89.2%
FUNDAMENTALS
Market Cap $8M
P/E Ratio (TTM) N/A
Forward P/E -0.3x
EPS (TTM) $-3.33
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.26
52-Week High $17.2
Current Price $0.6
Bear Target $5.0
Bull Target $40.0
● Now $0.6 ● Target $25.0
TRADING DATA
Avg Volume 550K
YTD Return -89.2%
Analyst Count 3
Consensus Hold
Upside to Target +4066.7%
Last Updated 2026-06-27

ANALYST SUMMARY

Reviva Pharmaceuticals Holdings, Inc. (RVPH) is currently trading at $0.6 with a Wall Street consensus price target of $25.0, implying potential upside of 4066.7% over the next 12 months. 3 analysts currently cover RVPH, with a consensus rating of Hold — 67% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $40.0, while the most cautious has a target of $5.0.

RVPH operates in the Healthcare sector with a market capitalisation of $8M. The stock is down 89.2% year-to-date and is currently trading near the lower end of its 52-week range of $0.26 – $17.2.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for RVPH, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Maxim Group ↓ Downgrade
Buy → Hold 2026-04-08 28% win rate (40 calls)
Roth Capital — Reiterated
Buy → Buy 2026-03-31 Building track record
Alliance Global Partners — Reiterated
Buy → Buy 2026-03-30 14% win rate (7 calls)
D. Boral Capital ↓ Downgrade
Buy → Hold 2026-03-05 32% win rate (25 calls)
Chardan Capital — Reiterated
Buy → Buy 2026-01-05 33% win rate (6 calls)
D. Boral Capital — Reiterated
Buy → Buy 2025-12-23 32% win rate (25 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-12-23 31% win rate (48 calls)
D. Boral Capital — Reiterated
Buy → Buy 2025-11-19 32% win rate (25 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →